825P CemiplimAb-rwlc Survivorship and Epidemiology (CASE): A prospective study of the safety and efficacy of cemiplimab in patients (pts) with advanced cutaneous squamous cell carcinoma (CSCC) in a real-world setting
Authors:
- G. RabinowitsGRG. Rabinowits
- J. HomsiJHJ. Homsi
- S.J. ParkSPS.J. Park
- N. KhushanlaniNKN. Khushanlani
- T. PanellaTPT. Panella
- D.M. EllisonDED.M. Ellison
- R.W. GentryRGR.W. Gentry
- S.S. VennaSVS.S. Venna
- J. StrasswimmerJSJ. Strasswimmer
- R.M. ZunigaRZR.M. Zuniga
- S. ChandraSCS. Chandra
- E.S. RuizERE.S. Ruiz
- 13 September 2022
- journal article
- abstracts
- Published by Elsevier in Annals of Oncology
- Vol. 33 (7) , S925-S926